BioCryst Pharma BCRX Q3 2026: Revenue Beats and Guidance Raised

BioCryst Pharmaceuticals posted Q3 2026 revenue of $180.3 million, clearing the consensus estimate of $165.7 million by roughly 9%. GAAP earnings per share came in at $0.14, about 22% above the $0.115 estimate. Net income reached $37.9 million, more than tripling on a year-over-year basis.

ORLADEYO, the company's hereditary angioedema treatment, was the primary driver of the quarter, contributing $174.8 million of the total $180.3 million in revenue. Management did flag that some of the upside came from an initial inventory build at CareMed, which became BioCryst's sole-source specialty pharmacy in August. The company said it expects CareMed's inventory level to remain relatively stable going forward, so the stocking tailwind is not expected to repeat at the same scale.

The GAAP results absorbed restructuring charges tied to the closure of BioCryst's Birmingham research site, including $6.3 million in cash costs and $9.3 million in non-cash impairment charges recorded within R&D. The Birmingham closure is expected to be substantially complete by year-end and is projected to generate annual savings of $30 million to $35 million at a total cash cost of about $10 million.

Despite those one-time charges, BioCryst raised its full-year 2026 total revenue guidance to a range of $715 million to $730 million, up from the prior range of $690 million to $715 million. The company kept its ORLADEYO-specific revenue outlook steady at $625 million to $645 million; the guidance lift was driven by higher navenibart European licensing revenue and increased international RAPIVAB orders. Full-year non-GAAP operating expense guidance also improved, narrowing to $415 million to $425 million from $420 million to $440 million.

On the pipeline, the FDA approved ORLADEYO oral pellets in October for patients aged 12 and older, extending a formulation that had already launched in August for younger pediatric patients aged 2 to under 12. CEO Charlie Gayer noted that early reimbursement for the pediatric pellets was strong and new prescriptions came in ahead of expectations. Separately, the company expects initial data from BCX17725, its KLK5 inhibitor being studied in Netherton syndrome, by the end of 2026, with pivotal top-line results for navenibart anticipated in Q3 2027.